Oligonucleotide (siRNA) · Gene silencing: DUX4 · developed by Sarepta Therapeutics
SRP-1001 (ARO-DUX4) is an intravenously infused agent studied in facioscapulohumeral muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06131983 | Phase 1/2 | Muscular Dystrophy, Facioscapulohumeral | Enrolling by invitation | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Muscular Dystrophy, Facioscapulohumeral
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →